-
淋巴瘤是一组源于淋巴结或其他淋巴组织的恶性肿瘤。其治疗主要以化学治疗、放射治疗及生物靶向治疗为主。18F-FDGPET-CT是一种反映能量代谢底物葡萄糖跨膜转运速率和数量的分子影像技术, 可以通过“一站式”显像发现全身几乎所有被侵犯的淋巴结和结外器官。目前, 18F-FDG PET-CT已经被作为淋巴瘤的初始分期、再分期及疗效随访的标准影像技术。本文就18F-FDGPET-CT在淋巴瘤疗效评价及预后中的应用进行综述。
18F-FDG PET-CT评价淋巴瘤疗效及预后的价值
The value of18F-FDG PET-CT in lymphoma therapy evaluation and prognosis
-
摘要: 18F-FDG PET-CT作为一种反映能量代谢底物葡萄糖跨膜转运速率和数量的分子影像技术,目前已经被作为恶性淋巴瘤的初始分期、再分期及疗效随访的标准影像技术。但其在淋巴瘤疗效评价及预后中的应用价值尚未明确,该文就近年来18F-FDG PET-CT在淋巴瘤疗效评价及预后中的研究进展进行综述。
-
关键词:
- 淋巴瘤 /
- 氟脱氧葡萄糖F18 /
- 正电子发射断层显像术
Abstract: 18F-FDG PET-CT as a molecular imaging technology for velocity rate and quantity of FDG has become a standard imaging technique for staging and follow-up of lymphoma.However, its value in therapy evaluation and prognosis is not very clear.This article summarizes some related papers in recent years and reviews its value in therapy evaluation and prognosis of lymphoma.-
Key words:
- Lymphoma /
- Fluorodeoxyglucose F18 /
- Positron-emission tomography
-
[1] Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, et al. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica, 2006, 91(4): 522-529. [2] Terasawa T, Nihashi T, Hotta T, et al. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review. J Nucl Med, 2008, 49(1): 13-21. doi: 10.2967/jnumed.107.039867 [3] Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol, 2005, 23(21): 4652-4661. doi: 10.1200/JCO.2005.01.891 [4] Picardi M, De Renzo A, Pane F, et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma, 2007, 48(9): 1721-1727. doi: 10.1080/10428190701559140 [5] Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol, 2005, 16(9): 1514-1523. doi: 10.1093/annonc/mdi272 [6] Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol, 2002, 13(9): 1356-1363. doi: 10.1093/annonc/mdf256 [7] Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood, 2006, 107(1): 52-59. doi: 10.1182/blood-2005-06-2252 [8] Mikhaeel NG. Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now?. Leuk Lymphoma, 2009, 50(12): 1931-1936. doi: 10.3109/10428190903275610 [9] Terasawa T, Dahabreh IJ, Nihashi T. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis. Oncologist, 2010, 15(7): 750-759. doi: 10.1634/theoncologist.2010-0054 [10] Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med, 2007, 48(10): 1626-1632. doi: 10.2967/jnumed.107.042093 [11] Torizuka T, Nakamura F, Kanno T, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging, 2004, 31(1): 22-28. doi: 10.1007/s00259-003-1333-8 [12] Itti E, Juweid ME, Haioun C, et al. Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background. J Nucl Med, 2010, 51(12): 1857-1862. doi: 10.2967/jnumed.110.080556 [13] Crocchiolo R, Canevari C, Assanelli A, et al. Pre-transplant 18FDGPET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leuk Lymphoma, 2008, 49(4): 727-733. doi: 10.1080/10428190701885545
计量
- 文章访问数: 1901
- HTML全文浏览量: 641
- PDF下载量: 15